Owlstone Medical celebrates success at SME Cambridgeshire Business Awards
It was a double success as the Owlstone Medical team scooped two awards. The company won Website of the Year for its OMED Health website and silver for Employer of the Year.
Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease
$5 million equity investment and initial $1.5 million grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the de
Owlstone Medical presents data demonstrating progress in development of Breath Biopsy tests for Liver Cirrhosis and NASH
Data presented at EASL Congress 2023, Austria, 21-24 June
Owlstone Medical presents data demonstrating progress in development of breath biopsy test for the early detection of lung cancer
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announces new data on the development of a screening test for the early detection of lung cancer.
Owlstone Medical wins contract from U.S. Department of Defense to develop handheld breath biopsy device for early infectious disease detection
Initial award recognizes potential of proprietary Owlstone Medical technology for non-invasive viral and bacterial respiratory infectious disease detection
Owlstone Medical launches OMED Health to enable patients to better understand their gut microbiome and manage their digestive health
Breath-based analysis technology and digital platform offers a science-backed approach to helping individuals monitor and treat their gut health and understand their microbiome
Owlstone Medical enters partnership with Bicycle Therapeutics for the development of Antigen-Targeted EVOC Probes for early Cancer detection
Cambridge, UK - Owlstone Medical , the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announces that it has entered into a Research Agreement with Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology.
Owlstone Medical publishes data on the use of exhaled volatile organic compounds as biomarkers for liver disease detection
Study published in Journal of Clinical and Translational Hepatology demonstrates alterations in breath VOCs can be used to differentially identify liver disease on breath
Owlstone Medical launches Breath Biopsy VOC Atlas
Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the launch of the Breath Biopsy VOC Atlas, a catalogue of validated and qua
Owlstone Medical appoints Mark Capone to Board of Directors
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the appointment of Mark Capone, former President and CEO of Myriad Genetics, to its Board as an independent non-executive director. Following this appointment, the Owlstone Medical Board comprises seven members including one executive director and two…
Owlstone Medical closes £42m oversubscribed financing round to continue to advance breath biopsy
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the close of its Series D financing round. Due to the high level of interest in this capital raise, the company has significantly exceeded its $50 million target, securing $58 million in funding (c. £42 million) and bringing the total raised by the Company to…
Owlstone Medical publishes data on the use of face mask filters to capture viral particles for SARS-CoV-2 detection
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the publication of a peer-reviewed study in 'Nature Scientific Reports'1. The paper investigates the performance of filters embedded in face masks for supporting the detection of SARS-CoV-2 as an alternative to nasopharyngeal swabs (NPS).
Owlstone Medical's annual Breath Biopsy Conference is online this autumn
Owlstone Medical's next Breath Biopsy Conference (BBCon21) will be held on the 12th & 13th October. The firm is keen to keep reaching global audiences, and this year’s event will be online and free to attend. Registration is open now.
Owlstone Medical launches breath testing for digestive health
Owlstone Medical (OML), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced agreements with Functional Gut Clinic (FGC) and Functional Gut Diagnostics (FGD), leading providers of smart solutions for the diagnosis of gut health problems.
Owlstone Medical introduces Breath Biopsy Panel for respiratory diseases
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today introduced the Respiratory Diseases Research Use Only (RUO) Panel.
7 highlights from 2020: An exciting year of progress for Owlstone Medical
2020, as a consequence of COVID-19, has seen a greatly increased level of international interest in the fast-growing field of breath research. As this globally challenging year is now at an end, Owlstone Medical has taken a look back at what it has achieved for Breath Biopsy®.
Owlstone Medical expands US operations and establishes permanent US office
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces that it has taken important steps to better support its pharmaceutical and academic customers in the United States by establishing a permanent office and expanding its highly skilled local team.
Owlstone Medical announces key study results on use of breath biopsy for improved detection of liver disease
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the results of a patient study that successfully demonstrates the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease.
Owlstone Medical appoints Neil Tween as Chief Financial Officer
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces the appointment of Neil Tween as its new Chief Financial Officer.
Owlstone Medical named as one of FierceMedTech’s “Fierce 15” companies of 2019
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it has been named by FierceMedTech as one of 2019’s Fierce 15.
Owlstone Medical joins EU-funded EPHOR consortium to advance occupational health science
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has joined the EU-funded Exposome Project for Health and Occupational Research (EPHOR). The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes…
Breath Biopsy Conference doubles in size
The 2019 Breath Biopsy Conference – Owlstone Medical's community meeting for breath researchers – took place in Cambridge on 13th and 14th November.
Owlstone Medical enters collaboration to advance early disease detection using non-invasive breath biopsy
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine…
Owlstone Medical to contribute breath biopsy to 3TR, the largest-ever IMI2 immunology project
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine has joined 3TR, a large-scale public-private research initiative that aims to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases.
Cleveland Clinic and Owlstone Medical partner to establish a new Center for Early Disease Detection
Cleveland Clinic is partnering with Owlstone Medical to establish a new Center for Early Disease Detection. The Center will investigate the use of measuring and quantifying volatile organic compounds (VOCs) in exhaled breath, in combination with other non-invasive biomarkers from other bodily fluids such as saliva and blood, for the early detection of multiple diseases from chronic conditions to…